ABSTRACT SUBMISSION GUIDELINES
The Canadian Cardiovascular Congress (CCC) is the largest gathering of cardiovascular health professionals and researchers in Canada, drawing participants from across the country and around the globe. The CCC is a unique opportunity for updating and maintaining scientific knowledge through accredited education opportunities, while also providing an ideal forum for networking, and research advancement. We are currently seeking submissions for abstracts for this year’s CCC.
These abstract submission guidelines contain the following sections:
- Submission Fee
- Submission Deadline
- Submission Method
- General Submission Guidelines
- Character Count and Writing Standards
- Authorship Requirements and Conflict of Interest Disclosure Statement
- Encore Presentations
- Presentation Types
- Abstract Award Criteria
- Abstract Review
- Abstract Selection Criteria
- Abstract Rejection Criteria
- Abstract Status
- Abstract Withdrawal
- Embargo Policy
- Technical Support
Submission Fee
There is no submission fee .
Submission Deadline
Abstracts must be received electronically through the online submission system.
Abstract Submission site opens: Wednesday, February 21
Abstract Submission site closes: Tuesday, May 7, 12:00 noon (EDT).
Faxed, mailed or emailed abstract submissions will not be accepted.
The online submission system will identify your submitted abstract as either complete or incomplete. If incomplete, the system will flag the tasks that require attention and completion. Incomplete submissions at the time of the deadline will not be accepted. The submitter has until the deadline to complete the abstract submission without exception.
Submission Method
Upon successful submission through the online abstract submission website, the submitter will receive an acknowledgement of receipt by email.
Please email technical support if you did not receive your email confirmation within 48 hours after submitting your abstract. Changes to abstracts can be made before the deadline within the submission site. A link to your profile will be posted in your confirmation email.
General Stream Submission Guidelines
- There is no limit to the number of abstracts an individual may submit.
- Submitters may return to the online system to edit abstracts, revise information, or delete abstracts at any time before the submission deadline . After the submission deadline, the online submission system will be closed and completed abstracts will be included in the peer review process.
- Accepted general stream abstracts will be published as submitted. Authors whose abstracts are accepted give permission and authority to have their abstract published, without compensation.
- Accepted abstracts will also be available for viewing in the online publication, in the event app and/or the event platform.
- No change in abstract title, content, and names or order of authors will be accepted after the submission deadline, May 7, 12:00 noon EDT.
- A submitter should not “split” data to create several abstracts from one. If splitting is judged to have occurred, scores of related abstracts will be reduced.
- Abstracts containing identical or nearly identical data submitted from the same institution and/or individuals may be disqualified.
- Submission of an abstract constitutes a commitment by all author(s) as to the integrity of the data and that they agree with the submission.
- If the research presented in the abstract has been funded or supported, in whole or in part, by a grant, please indicate so during the submission process. Accepted abstracts with funding will be highlighted in the publication(s). Responses provided to this question will not affect the acceptance of the abstract.
- Abstracts should be written and submitted by physicians, researchers, trainees, healthcare professionals or patient partners. Research funded by industry that has been approved by a Research Ethics Board, and for which the principal investigator/principal author is not an employee of the funding company, will be accepted for review. Abstracts submitted by pharmaceutical companies, or device companies, with employees as principal investigators/principal authors WILL NOT be accepted.
- If submitting a related abstract to multiple national and/or international meetings, please ensure that you are fully aware of the submission guidelines and regulations for all meetings.
Character Count and Writing Standards
The word limit for a submission is a maximum of 400 words. Tables, graphs, and images must be added under the ‘Supporting images, graphs or tables task during the submission process, and are not included in the word limit. Please limit to a maximum of two tables and/or images. Graphs and tables must be simple and easily interpreted. They also must be of high resolution.
Abstracts are published as submitted. Please proofread your work carefully to avoid errors.
All abstracts must be written in English with accurate grammar and spelling. Abstracts WILL NOT be edited by conference staff. Typographical and grammatical errors will appear as submitted. Revisions or corrections to abstracts will not be permitted once abstracts are accepted.
Using the following section titles in your submission will help direct the focus of the abstract:
a) BACKGROUND: A brief statement of the purpose.
b) METHODS/RESULTS: A statement of the method(s) of investigation and a summary of the results presented in sufficient detail to support conclusions.
c) CONCLUSION: A brief statement of results reached – Statements such as “results to be discussed” or “data will be presented” are not sufficient and will result in rejection of the abstract.
Abstracts must adhere to the following format:
- All abstract titles must be capitalized.
- Author(s) first name and last name should be listed in all caps.
- If an author’s name appears on more than one abstract, their names must appear the same way on all abstracts, as that author would enter it. This consistency will streamline the process of facilitating proper indexing in both the App and all publications. Do not list authors with initials only.
- The use of standard abbreviations is required. Examples include kg, g, mg, mL, L, meq, m, mmol/L, and %. Abbreviated terms should be expanded at first mention with the abbreviation in parentheses. The abbreviation can then be used throughout the rest of the abstract. Use numerals to indicate numbers, except when beginning sentences.
- Following the National Standard of Support for Accredited CPD Activities, it is required that any description of therapeutic options utilize generic names and not reflect exclusivity and branding.
- Special symbols may be included in the abstract body, however, conference staff will not be responsible for any symbols, graphics, fonts or special characters which do not appear or are lost in translation due to software or hardware incompatibilities with the file submitted.
- Language can have a profound impact on the lives of people. Inappropriate language has a negative impact on self-efficacy, well-being, and confidence which can seriously undermine experiences with health-care providers and, more broadly, can contribute to stigma. We encourage you to use language that promotes and guides the use of inclusive, equitable, and value-based language in clinical practice, health-care, and research settings. We hope that greater attention to the language used will contribute to enhancing public understanding, decreasing the stigma, stereotypes, and associated prejudices.
Authorship Requirements and Conflict of Interest Disclosure Statement
There is no limit to the number of abstracts an author may submit; however, it is the author’s responsibility to designate a separate presenting author for scheduling conflicts that arise due to multiple submissions.
The first author will have the option to self-identify as a trainee, early career (first 7 years), or regular CCS member.
The submitting author will receive notification of abstract status. Should the submitter prefer, a different email address may be submitted for abstract correspondence and notification of abstract status.
For accepted abstracts, the first author is expected to present the work. If the first author is unable to present, they must delegate another presenting author from the co-author(s) listed on the abstract at the time of submission.
All author(s) must complete the conflict disclosure form included as a task within the submission site.
For each abstract submitted, a conflict-of-interest disclosure form identifying commercial relationships must be completed online for each author (prompted by the online submission system). The submitting author is to ensure all conflicts are identified for all authors and can complete the disclosure on behalf of all authors, but must be done so in consultation with each individual listed. By disclosing any direct or indirect conflicts of interest, the submitter authorizes the host organization to disclose conflict. Disclosure information for accepted abstracts will be made available upon request.
Encore Presentations
Abstracts accepted for presentation at other national and international conferences occuring between CCC 2023 and CCC 2024 may be submitted to CCC 2024, however, they must:
- Be submitted as an Encore abstract presentation.
- Include the name of the meeting and date on which the paper was originally presented.
- If published, include the publication journal name, publication date and a link to the original abstract publication.
Please note, encore presentation submissions will be screened under the same criteria as other contributed papers.
*Note: Abstracts not submitted as Encore Presentations must not have been published as a journal manuscript or an abstract prior to CCC 2024 (October 24-27, 2024).
Presentation Types
During the submission process submitters will be asked their presentation preference; oral presentation or poster presentation.
The selection of oral or poster preference will neither prejudice acceptance nor guarantee oral or poster presentation, as abstracts must be arranged to fit into a thematic group for presentation. However, the Program Committee will make every effort to accommodate your presentation request.
Abstract Award Criteria
For CCS Submissions:
During the submission process submitters may apply for the following awards. For more information and award eligibility criteria please click on the award name.
Abstract Review
Abstracts submitted under the host organization Canadian Cardiovascular Society will be reviewed in the following tracks:
- BSCI: Basic and translational Science
- CAD General: Chronic Coronary Artery Disease, Cardio-oncology
- CAD ACS & AMI: ACS, AMI, Critical care for cardiovascular diseases, Mechanical circulatory support
- CSI: Coronary and Structural Intervention, PCI, Interventional procedures.
- CONG: Pediatrics and Congenital Heart Disease.
- EP: Electrophysiology, Sudden Cardiac Death, Arrhythmia.
- EDU: The process of educational learning and dissemination of knowledge or skills relevant to cardiovascular sciences.
- HF: Heart Failure, Heart Function, Cardiomyopathy, Transplant, Cardio-oncology, Mechanical circulatory support.
- IMAG: Imaging Techniques, Nuclear Cardiology, MRI, Echo, Cardio-oncology.
- NURSING: The specialty of Cardiovascular nursing.
- PREV: Prevention, Rehabilitation, Hypertension, Diabetes, Lipids
- PLCY: Quality improvement, healthcare policy and administration related to cardiovascular sciences.
- SURG: Cardiac Surgery and Anesthesia.
- VASC: Vascular disease and vascular complications, specifically impacting non-coronary vasculature, such as the cerebral arteries, lower extremity arteries, aorta, or pulmonary arteries.
Abstract Selection Criteria
Abstract grading is performed by blinded review by a group of experts within a particular field. The review committee is responsible for grouping the abstracts appropriately for a particular specialty or association. Abstracts are selected based on scientific criteria of merit, originality of work, adequacy of data, and clarity of exposition.
To view the full Abstract Scoring Criteria, please click here.
Abstract Rejection Criteria
Abstract will be rejected if:
- Abstract did not conform to instructions.
- Abstract lacks data or includes inconsistent/ambiguous data.
- Abstract is not well-organized, information is dated, the importance of the topic is not clear, discussion of study results is vague, or conclusion is not supportable based on the data presented.
- Clinical research did not abide by the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans
The final decision with respect to selection, programming, and/or publication of any abstract will be made by the Program Committee.
Abstract Status
All abstracts submitted must comply with these guidelines to be considered for acceptance. The final decision with respect to selection, programming, and/or publication of any abstract will be made by the Program Committees.
Notification of acceptance or rejection of abstracts will be emailed in July. Submitters can also check the status of their submission online through the online submission system in July. All appropriate accompanying materials, including guidelines for oral or poster presentations, will be sent by email to the presenting author in July.
Abstract Withdrawal
Withdrawal of accepted abstracts must be received at abstracts@ccs.ca, no later than July 31 to avoid publication.
Embargo Policy
Embargo Date and Time: October 1, 2024 at Noon EDT
The embargo policy for submitted abstracts:
- Accepted abstracts may not be published, broadcasted, posted online or placed in the public domain before the embargo date and time. All accepted abstracts are embargoed until the posted embargo date and time.
- Abstract authors can present the findings of their submitted papers with experts for comment and at professional meetings to colleagues, but should be clearly identified as embargoed and include the embargo date and time. It is the responsibility of the authors to ensure embargo policies are honoured by third parties. Should an author be planning to make such a presentation, we ask the author to inform the submitting organization of those intentions.
- The press may not distribute embargoed materials in the public domain before the embargo date. However, embargoed materials may be distributed to the media by press officers up to seven days before the embargo date. Press releases must be clearly identified as embargoed and must include the embargo date and time. It is the press officer’s responsibility to ensure embargo policies are honoured by third parties.
- Participation in news conferences is open after the posted embargo date and time.
Should you have any questions about the embargo policy, please contact abstracts@ccs.ca
Technical Supports
If you have questions about completing the abstract form, please contact Canadian Cardiovascular Society (CCS).
Email: abstracts@ccs.ca
